MEDISAFE

Short name: CBRN CoE Project 66 MEDISAFE
Title: MEDISAFE Combating falsified medicines in Eastern and Central Africa
Geographical Scope: Eastern and Central Africa

Participating Countries (to be confirmed): Burundi, Democratic Republic of the Congo (DRC), Ethiopia, Ghana, Kenya, Malawi, Rwanda, Seychelles, Tanzania, Uganda, Zambia

Duration: 3 years
Role: Partner for Work Packages 1, 2, 3
Consortium LeaderExpertise France (AFETI), France
Contracting Authority: EU Commission, DG DEVCO


OBJECTIVES

The objective of the project is to support the fight against the production and trafficking of falsified medicines and medicinal products through a regional approach. The strategy is articulated around 3 pillars:

Prevention of the manufacturing, sale and consumption of substandard and falsified medical products for secure supply and quality demand;

Detection of any substandard or falsified product that is already in the supply chain;

Response in order to protect public health.

ACTIVITIES

The project will be implemented through the following activities:

– Planning of the project implementation by assessing its context, status, previous project achievements and needs in the field of response to CBRN event and by coordinating with other CoE’s projects about the objectives, deliverables, activities and results in agreement with the partners countries, including the CoE Regional Secretariats and the concerned National Focal Points (WP0);

– Raising of education and awareness among all stakeholders, providing accurate and balanced information on the risks of substandard and falsified medical products and promoting rational use of medicines (WP1);

– Building of a comprehensive legal framework in order to ensure a high level of public health protection and the quality, safety and efficacy of authorised medicines (WP2);

– Improvement of technical capabilities to address the falsified medicines and medicinal products challenge, such as screening technologies and technical capacities for inspection in order to enhance investigation in case of suspicion of falsified products (WP3);

– Promotion of interagency cooperation, building trust amongst public sector entities themselves and with the private sector (i.e. pharmaceutical companies) (WP4);

– Enhancement of international cooperation concerning falsified medicines and medicinal products, through the promotion of information exchange between partners (WP5);

– Protection of supply chain integrity through the identification of pharmaceutical industries, importers and other stakeholders in order to detect breach, together with the fight against the use of the internet as a support to the distribution of counterfeit medicines (WP6)

Logo Sacco 2016UNIMI_BAN_blu3righe